Stereotactic Body Radiotherapy for Early-Stage Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline

Bryan J. Schneider, Megan E. Daly, Erin B. Kennedy, Mara B. Antonoff, Stephen Broderick, Jill Feldman, Shruti Jolly, Bryan Meyers, Gaetano Rocco, Chad Rusthoven, Ben J. Slotman, Daniel H. Sterman, and Brendon M. Stiles

ABSTRACT

Purpose
The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on treatment with stereotactic body radiotherapy (SBRT) for patients with early-stage non–small-cell lung cancer. ASCO has a policy and set of procedures for endorsing and/or adapting clinical practice guidelines that have been developed by other professional organizations.

Methods
The ASTRO Evidence-Based Guideline for Stereotactic Body Radiotherapy for Early-Stage Non–Small-Cell Lung Cancer was reviewed for developmental rigor by methodologists. An ASCO Expert Panel updated the literature search and reviewed the guideline content and recommendations.

Results
The ASCO Expert Panel determined that the recommendations from the ASTRO guideline, published in 2017, are clear, thorough, and based on the most relevant scientific evidence. ASCO statements and minor modifications were added to enhance the applicability of the ASTRO guideline for the broader ASCO audience.

Recommendations
For standard operative risk patients with stage I NSCLC, SBRT is not recommended outside of a clinical trial. Lobectomy with systematic lymph node evaluation remains the recommended treatment, although a sublobar resection may be considered in select clinical scenarios. Recommendations are provided regarding the use of SBRT in high operative risk patients and for inoperative patients, including in challenging scenarios where tumors are: centrally located, >5 cm in diameter, lacking tissue diagnosis, synchronous primary or multifocal, second primary after pneumonectomy, proximal to or involved with mediastinal structures, abutting the chest wall, or recurring after previous treatment. Qualifying statements are included to provide further guidance for implementation, and the importance of a discussion of treatment options among members of the multidisciplinary cancer care team is emphasized. Additional information is available at: www.asco.org/thoracic-cancer-guidelines and www.asco.org/guidelineswiki.

J Clin Oncol 36:710-719. © 2017 by American Society of Clinical Oncology

INTRODUCTION

More than 155,000 estimated deaths will be attributable to non–small-cell lung cancer (NSCLC) in the United States in 2017, making it the leading cause of cancer death for both men and women. Approximately 16% of new cases will be early-stage localized tumors. According to the 7th edition of the American Joint Committee on Cancer staging system, these are T1 or T2 tumors with no regional lymph node or distant metastases.
THE BOTTOM LINE

Stereotactic Body Radiotherapy for Early-Stage Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline

Guideline Questions
For patients with early-stage (T1-2, N0) NSCLC:

- When is SBRT appropriate for operable or inoperable patients?
- For medically inoperable patients, how can SBRT techniques be individually tailored in high-risk clinical scenarios?
- For medically inoperable patients, what is the role of SBRT as salvage therapy for early-stage lung cancer that recurs?

Target Population
Operable and inoperable patients with early-stage NSCLC.

Target Audience
Members of the multidisciplinary team, including surgical oncologists, radiation oncologists, medical oncologists, pulmonologists, and other health care providers.

ASCO Key Recommendations for SBRT for Early-Stage NSCLC
The recommendation statements outlined below include ASTRO’s ratings of evidence quality and strength of recommendations. The ASCO Expert Panel’s modifications and qualifying statements to ASTRO’s recommendations appear in bold. A list of the original ASTRO recommendations can be found in Appendix Table A1 (online only). References to staging in this document are based on the 7th edition of the American Joint Committee on Cancer staging system.

Part 1. Recommendations for SBRT for patients with T1-2, N0 NSCLC who are medically operable.

- Recommendation 1A. Patients with stage I NSCLC should be evaluated by a thoracic surgeon, preferably within a multidisciplinary cancer care team, to determine operability. The decision to undergo an operation should be made by the surgeon and patient, in collaboration with family members. Some criteria that have been used to define operative risk are listed in the qualifying statements below (Strength of recommendation: strong; Quality of evidence: moderate).

- Recommendation 1B. For patients with standard operative risk and stage I NSCLC, SBRT is not recommended as an alternative to surgery outside of a clinical trial. Discussions about SBRT among members of the multidisciplinary cancer care team may be appropriate. For this population, lobectomy with systematic mediastinal/hilar lymph node evaluation remains the recommended treatment, though a sublobar resection may be considered in select clinical scenarios (Strength of recommendation: strong; Quality of evidence: high).

- Recommendation 1C. For patients with high operative risk stage I NSCLC, discussions about SBRT as a potential alternative to surgery are encouraged within the multidisciplinary cancer care team. In cases where SBRT is offered, patients should be informed that while SBRT may have decreased risks from treatment in the short term, the longer-term outcomes > 3 years are not well established (Strength of recommendation: conditional; Quality of evidence: moderate).

- ASCO qualifying statement: Where multidisciplinary consultation and patient preference result in a decision to perform resection in high operative risk patients, limited resection (segmentectomy or wedge resection), rather than lobectomy, is more commonly selected. At this time, there have been no prospective randomized trials completed that directly compare limited resection with SBRT.

- ASCO qualifying statement: Longer-term data from the RTOG 0236 phase II trial of inoperable T1-T2N0M0 tumors ≤ 5 cm showed that rates of 5-year primary tumor, in- lobe, and locoregional failure were 7%, 20%, and 38%, respectively. Overall survival at 5 years was 40%. Treatment-related grade 3, grade 4, and grade 5 adverse events were reported in 27%, 4%, and 0% of patients, respectively.3

- ASTRO qualifying statement: While there is no universally accepted definition, high operative risk has been defined by various studies as “FEV1 ≤ 50% predicted, diffusing capacity of the lungs for carbon monoxide < 50% predicted, or a combination of advanced age, impaired pulmonary function, pulmonary hypertension, and poor left ventricular function. A thoracic surgeon who specializes in lung resections remains the best person to assess operative risk.”31(p99)

(continued on following page)
Part 2. Recommendations for SBRT for medically inoperable patients with T1-2, N0 NSCLC.

With centrally located tumors:

- **Recommendation 2A.** SBRT directed toward centrally located lung tumors carries unique and significant risks when compared with treatment directed at peripherally located tumors. The use of 3 fraction regimens is **not recommended** in this setting (Strength of recommendation: strong; Quality of evidence: high).

ASCO qualifying statement: There is a significant rate of nodal disease in this population; therefore, pretreatment staging with positron emission tomography (PET)/computed tomography (CT) and invasive mediastinal/hilar staging with endobronchial ultrasound (EBUS)/mediastinoscopy is recommended.

- **Recommendation 2B.** Providers should use caution when considering SBRT for central tumors. **Delivery of SBRT in more than 3 (ie, 4 or 5) fractions may reduce the risk of severe toxicity.** Adherence to volumetric and maximum dose constraints may optimize the safety profile of this treatment. For central tumors for which SBRT is deemed too high-risk (eg, tumors directly abutting or invading the esophagus or proximal bronchial tree), hypofractionated radiotherapy utilizing 6-15 fractions or **conventionally fractionated radiotherapy may** be considered (Strength of recommendation: conditional; Quality of evidence: moderate).

ASTRO qualifying statement: Caution is recommended due to the potential for serious toxicity to normal centrally located tissues. “In this setting, adequate informed consent to patients—including a discussion of patient risk tolerance and goals of care—is a necessary part of communication between radiation oncologists and patients.”3(p12)

ASCO qualifying statement: The RTOG 0813 phase I/II study aimed to evaluate escalating radiation doses ranging from 50 to 60 Gy in five fractions delivered every other day to central tumors ≤ 5 cm (including tumors within 2 cm of the tracheobronchial tree, and abutting the pericardium, mediastinum, or spine). Four patients, including one treated to 10.5 Gy × 5, two treated to 11.5 Gy × 5, and one treated to 12 Gy × 5, experienced grade 5 or fatal adverse events, while those treated at the lowest dose level did not experience any grade ≥ 3 events. We are currently awaiting mature, long-term efficacy results presented in full manuscript form from this trial. These results will be used to determine whether there is a dose that results in an acceptable balance of tumor control and toxicity.

**Recommended 2C.** SBRT may be an appropriate option for select tumors > 5 cm in diameter with an acceptable therapeutic ratio. Adherence to volumetric and maximum dose constraints may optimize the safety profile of this treatment (Strength of recommendation: conditional; Quality of evidence: low).

- **Recommendation 2D.** Whenever possible, obtain a biopsy prior to treatment with SBRT to confirm a histologic diagnosis of a malignant lung nodule (Strength of recommendation: strong; Quality of evidence: high).

- **Recommendation 2E.** SBRT may be delivered in patients who refuse a biopsy, have undergone nondiagnostic biopsy, or who are thought to be at prohibitive risks of biopsy. Prior to SBRT in patients lacking tissue confirmation of malignancy, **treatment options should be discussed within a multidisciplinary cancer care team** with a consensus that the lesion is radiographically and clinically consistent with a malignant lung lesion based on tumor, patient, and environmental factors (Strength of recommendation: strong; Quality of evidence: moderate).

ASTRO qualifying statement: Tumor-specific factors to consider include lesion size, growth over time, presence of spiculations or lack of benign-appearing calcifications, PET avidity, and lesion location. Other patient-specific factors, such as smoking history or history of prior lung cancers, should also be considered. Regional environmental factors, such as the incidence of histoplasmosis, may affect the probability that a lesion is malignant and should also be considered in the calculation of obtaining histologic confirmation.

ASCO qualifying statement: Patients should be staged with PET/CT and mediastinal/hilar nodal sampling when feasible.

ASCO qualifying statement: For patients deemed to be at prohibitive risk of biopsy, a multidisciplinary discussion should occur to ensure that safe means of obtaining tissue are not feasible (eg, transbronchial biopsy, etc). In addition, consideration should also be given as to whether SBRT would pose prohibitive risks. The goals, expectations, and potential increased risks of SBRT should be carefully weighed and discussed with the patient and family in the context of shared decision making.

(continued on following page)
For patients with synchronous primary or multifocal tumors:

- **Recommendation 2F.** Multiple primary lung cancers (MPLC) can be difficult to differentiate from intrathoracic metastatic lung cancer and pose unique issues for parenchymal preservation; therefore, it is recommended that they are evaluated by a multidisciplinary cancer care team (Strength of recommendation: strong; Quality of evidence: moderate).
- **Recommendation 2G.** PET/CT and brain MRI are recommended in patients suspected of having MPLC to help differentiate from intrathoracic metastatic lung cancer. Invasive mediastinal/hilar staging with EBUS/mediastinoscopy should be **strongly considered** (Strength of recommendation: strong; Quality of evidence: moderate).
- **Recommendation 2H.** SBRT may be considered by the multidisciplinary cancer care team as a potentially curative treatment option for patients with synchronous MPLC. (Strength of recommendation: conditional; Quality of evidence: low)

ASTRO qualifying statement: SBRT for synchronous MPLC has equivalent rates of local control and may have comparable toxicity but decreased rates of overall survival compared with SBRT for single tumors. The decision to treat multiple lesions with SBRT is an individualized process that should be discussed by a multidisciplinary cancer care team, as this approach may increase radiation doses to normal tissues and increase the risk of toxicity in some cases (Strength of recommendation: conditional; Quality of evidence: low).

- **Recommendation 2I.** SBRT may be considered by the multidisciplinary cancer care team as a potentially curative treatment option for patients with metachronous MPLC (Strength of recommendation: strong; Quality of evidence: moderate).

ASTRO qualifying statement: SBRT for metachronous MPLC has comparable rates of local control and toxicity and overall survival compared with single tumors. For patients who underwent pneumonectomy and now have a new primary tumor in their remaining lung:

- **Recommendation 2J.** SBRT may be considered by the multidisciplinary cancer care team as a potentially curative treatment option for patients with metachronous MPLC in a postpneumonectomy setting (Strength of recommendation: conditional; Quality of evidence: low).

ASTRO qualifying statement: “While SBRT for metachronous MPLC appears to have equivalent rates of local control and acceptable toxicity compared to single tumors, SBRT in the post-pneumonectomy setting might have a higher rate of toxicity than in patients with higher baseline lung capacity.” Delivery of SBRT would depend on tumor location, size, and patient comorbidities, and patients should be thoroughly evaluated by a multidisciplinary cancer care team. ASTRO qualifying statement: “Generally, great caution should be taken to minimize the dose to the single lung, as high-grade radiation pneumonitis in a single lung may be a serious and potentially life-threatening toxicity.” The potential for radiation pneumonitis should be discussed with patients, and a pulmonary evaluation should be obtained, including pulmonary function tests and consideration of a pulmonary evaluation by a dedicated pulmonologist.

**Part 3:** Recommendations for patients with tumors with intimal proximity/involvement of mediastinal structures (bronchial tree, esophagus, heart, etc.).

- **Recommendation 3A.** Providers should use caution when considering SBRT for tumors in close proximity to the proximal bronchial tree. Delivery of SBRT in 4-5 fractions may reduce the risks of severe toxicity. Physicians should endeavor to meet the constraints that have been used in prospective studies, given the severe toxicities that have been reported (Strength of recommendation: strong; Quality of evidence: low).

ASTRO qualifying statement: There are a limited number of retrospective studies that report the use of SBRT in patients with tumors abutting the proximal bronchial tree. Patients with tumors abutting the proximal airways should be counseled about the potential for fatal treatment complications, even when dose constraints and highly conformal SBRT techniques are used.

ASCO qualifying statement: Appropriate staging, including PET/CT and invasive mediastinal/hilar staging with EBUS/mediastinoscopy, are recommended due to the high risk of nodal disease in this patient population.

- **Recommendation 3B.** Where a discussion within the multidisciplinary cancer care team results in a recommendation for SBRT for tumors in close proximity to the esophagus, physicians should endeavor to meet the constraints that have been used in prospective studies or otherwise reported in the literature, given the severe esophageal toxicities that have been reported (Strength of recommendation: strong; Quality of evidence: low).

ASTRO qualifying statement: Severe, life-threatening esophageal toxicity is possible after SBRT. Despite limited data to support firm recommendations, dose to the esophagus should be carefully assessed and minimized. Highly conformal techniques can be used to facilitate esophageal avoidance with central tumors.

- **Recommendation 3C.** For tumors in close proximity to the heart and pericardium, SBRT should be delivered in 4-5 fractions with low incidence of serious toxicities to the heart, pericardium, and large vessels observed. Adherence to volumetric and maximum dose constraints used in prospective trials or reported in the literature may optimize the safety profile of this treatment (Strength of recommendation: strong; Quality of evidence: low).
For tumors abutting or invading the chest wall:

- Recommendation 3D. SBRT is an appropriate option for treatment and may be offered for T1-2 tumors that abut the chest wall. Grade 1 and 2 chest wall toxicity, presenting most commonly as pain due to rib fracture or irritation of the intercostal nerves, is a common occurrence post SBRT that usually resolves with conservative management. Patients with peripheral tumors approximating the chest wall should be counseled on the possibility of this common toxicity (Strength of recommendation: strong; Quality of evidence: high).

ASTRO qualifying statement: The volume of chest wall receiving SBRT has been identified as a predictor of chest wall toxicity; however, the use of highly conformal techniques to reduce this volume may increase dose to the ipsilateral lung. Thus “compromising coverage of the planning target volume (PTV) or PTV trimming away from the chest wall are not favored as techniques to meet chest wall constraints.”

- Recommendation 3E. Until further evidence becomes available to inform the topic, the ASCO Expert Panel defers a decision for or against endorsement of the use of SBRT in patients with cT3 disease due to chest wall invasion.

Part 4. Recommendations for the role of SBRT in medically inoperable patients, as salvage therapy for early-stage lung cancer that recurs.

- Recommendation 4A. The use of salvage SBRT after primary conventionally fractionated radiation may be offered to selected patients who are identified as appropriate candidates following a discussion among members of the multidisciplinary cancer care team (Strength of recommendation: conditional; Quality of evidence: low).

ASTRO qualifying statement: Patients should be informed of the risk of significant (including fatal) toxicities associated with SBRT as salvage therapy after conventionally fractionated radiation.

ASTRO qualifying statement: “For centrally located salvage SBRT after an in-field recurrence, … severe toxicities were more common than some other retrospective reports and included a 23% grade 3 pneumonitis risk, 6% grade 5 pneumonitis risk, and 6% grade 5 hemoptysis risk. The authors conclude that local control can be achieved but that the high-risk nature of these central in-field recurrences warrants caution due to significant risk of grade 5 fatal events.”

- Recommendation 4B. Patient selection for salvage SBRT after prior treatment, including primary conventionally fractionated radiation, SBRT, or sublobar resection, is a highly individualized process. Radiation oncologists should assess evidence-based patient, tumor, and treatment factors prior to treatment initiation (Strength of recommendation: strong; Quality of evidence: low).

ASTRO qualifying statement: “Salvage SBRT treatment plans should ideally be reviewed with medical physics and other radiation oncologists (in a peer review quality assurance setting) to ensure high-quality results to optimize patient selection, maximize local control and survival, and minimize treatment toxicities.”

ASTRO qualifying statement: Toxicities vary on an individual basis depending on patient’s health, prior treatment, comorbidities, etc and should be discussed within the multidisciplinary cancer care team. “Predictors of toxicity for SBRT salvage include central tumor location, in-field recurrence, larger treatment volumes, bilateral mediastinal primary PTV targets, composite lung V20 (the percentage of the lung volume [with subtraction of the volume involved by lung cancer] that receives radiation doses of 20 Gy or more) ≥ 30%, FEV₁ ≤ 65%, and poor baseline performance status.”

Patients’ values, goals, and preferences.

ASCO qualifying statement: In written comments, the ASCO Expert Panel Patient Representative noted that there is a lack of strong evidence for many of the guideline recommendations. Thus, the Representative emphasized the importance of shared decision making between physicians, patients, and families in this context, because benefits and risks can have a different meaning for each patient, and patients and families will vary in their values, goals, and preferences, depending on factors such as overall health, comorbidities, and age (J. Feldman, personal communication, April 2017).

**Additional Resources**

More information, including a Data Supplement, a Methodology Supplement, slide sets, and clinical tools and resources, is available at www.asco.org/thoracic-cancer-guidelines and www.asco.org/guidelineswiki. Patient information is available at www.cancer.net

A link to the ASTRO guideline can be found at http://www.practicalradonc.org/article/S1879-8500(17)30121-2/fulltext

ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care, and that all patients should have the opportunity to participate.
OVERVIEW OF THE ASCO GUIDELINE ENDORSEMENT PROCESS

ASCO has policies and procedures for endorsing and/or adapting practice guidelines that have been developed by other professional organizations, with the goal of increasing the number of high-quality, ASCO-vetted guidelines available to the ASCO membership. The process involves an assessment by ASCO staff of candidate guidelines for methodological quality using the Rigour of Development subscale of the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument (see Methodology Supplement for more detail). The ASTRO guideline for SBRT in early-stage lung cancer rated highly on the AGREE II instrument and was identified as a potential candidate for endorsement by ASCO. During the endorsement process, modifications and qualifying statements were made by the ASCO Expert Panel to improve the guideline's applicability to the broader ASCO guideline audience.

DISCLAIMER

The clinical practice guidelines and other guidance published herein are provided by the American Society of Clinical Oncology, Inc. (“ASCO”) to assist providers in clinical decision making. The information therein should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Further, the information is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. Recommendations reflect high, moderate, or low confidence that the recommendation reflects the net effect of a given course of action. The use of words like “must,” “must not,” “should,” and “should not” indicate that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ASCO provides this information on an “as is” basis, and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.

GUIDELINE AND CONFLICTS OF INTEREST

The Expert Panel was assembled in accordance with ASCO’s Conflict of Interest Policy Implementation for Clinical Practice Guidelines (“Policy,” found at http://www.asco.org/rwc). All members of the Expert Panel completed ASCO’s disclosure form, which requires disclosure of financial and other interests, including relationships with commercial entities that are reasonably likely to experience direct regulatory or commercial impact as a result of promulgation of the guideline. Categories for disclosure include employment; leadership; stock or other ownership; honoraria, consulting or advisory role; speaker’s bureau; research funding; patents, royalties, other intellectual property; expert testimony; travel, accommodations, expenses; and other relationships. In accordance with the Policy, the majority of the members of the Expert Panel did not disclose any relationships constituting a conflict under the Policy.

CLINICAL QUESTION(S) AND TARGET POPULATION

The ASTRO guideline addressed four key clinical questions regarding the treatment of early-stage NSCLC with SBRT: (1) When is SBRT appropriate for patients with T1-2, N0 NSCLC who are medically operable? (2) When is SBRT appropriate for medically inoperable patients with T1-2, N0 NSCLC who have (a) centrally located tumors, (b) tumors > 5 cm in diameter, (c) tissue high rates of toxicity because of limited ability to define and constrain treatment volumes with this technique. For these reasons, stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiation therapy or SABR, defined as “a strategy that employs very high (ie, ablative) doses of radiation delivered to the cancer target over 1-5 fractions with highly conformal techniques,” emerged as a treatment option. In the Radiation Therapy Oncology Group (RTOG) 0236 phase II trial of SBRT in inoperable patients with peripheral tumors ≤ 5 cm, 5-year estimates of primary tumor, involved-lobe, and locoregional failure were 7%, 13%, and 38%, respectively, after a median follow-up of 4 years. Due to difficulties with accrual, no phase III randomized controlled trials comparing SBRT to surgical resection have been completed to date; however, it is already widely used for early-stage peripherally located inoperable lung cancer and has shown encouraging results in patients who are not fit or healthy enough to undergo surgery.

The American Society of Radiation Oncology (ASTRO) has developed an evidence-based guideline for the use of SBRT in patients who are considered standard operative risk or high operative risk and those who present with more clinically challenging scenarios in terms of tumor size or location, as well as cases without tissue diagnosis or with tumors that are synchronous primary or multifocal, second primary after pneumonectomy, or recurrent after previous treatment. The ASCO Expert Panel (Appendix Table A2, online only) critically appraised the ASTRO guideline on SBRT for early-stage NSCLC and added minor clarifications and qualifying statements to the ASTRO recommendations to enhance the applicability of the guideline for the broader ASCO audience. This endorsement reinforces the recommendations provided in the ASTRO guideline and acknowledges the effort put forth by ASTRO to produce an evidence-based guideline informing practitioners who care for patients with early-stage NSCLC. The ASTRO recommendations are listed in the Bottom Line Box, with qualifying statements from the ASCO Expert Panel. The full ASTRO guideline is available at http://www.practicalradonc.org/article/S1879-8500(17)30121-2/fulltext, with supplemental material available at http://www.practicalradonc.org/article/S1879-8500(17)30121-2/addons.
confirmation (diagnosis) lacking, (d) synchronous primary or multifocal tumors, (e) undergone pneumonectomy and now have a new primary tumor in their remaining lung. (3) For patients who have medically inoperable early-stage lung cancer, how can SBRT techniques be individually tailored to provide an adequate dose for tumor eradication with minimal risk to normal structures in the following high-risk clinical scenarios: (a) tumors with intimal proximity/involvement of mediastinal structures (bronchial tree, esophagus, heart, etc), (b) tumors abutting or invading the chest wall. (4) In medically inoperable patients, what is the role of SBRT as salvage therapy for early-stage lung cancer that recurs (a) after conventionally fractionated radiotherapy, (b) after SBRT, (c) after sublobar resection? The target population for the ASTRO guideline is patients with early-stage operable or inoperable NSCLC cancer.

**METHODS AND RESULTS OF THE ASCO UPDATED LITERATURE REVIEW**

ASCO guidelines staff updated the ASTRO literature search. PubMed MEDLINE was searched from August 1, 2016 to April 1, 2017. The search was restricted to systematic reviews, meta-analyses, randomized controlled trials and observational studies published in English. The updated search for all questions yielded 319 records. Nine of these studies, including a systematic review and eight observational studies, met the inclusion criteria.

### CHARACTERISTICS AND QUALITY ASSESSMENT OF INCLUDED STUDIES

One systematic review of SBRT that included 34 studies of outcomes in 4,570 patients with mostly inoperable SBRT met the inclusion criteria for the updated literature review. Three studies using administrative data from large databases, including the Surveillance, Epidemiology, and End Results (SEER) database, and the National Cancer Database (NCDB) also met the inclusion criteria. The NCDB includes data for approximately 70% of patients with NSCLC in the United States, while SEER is a collection of registry data on cancer cases from various locations and sources throughout the United States (http://seer.cancer.gov/about). These large database studies included an analysis of 5,821 elderly patients ≥ 65 years of age, a study of > 15,000 patients who were free of the comorbid conditions that can frequently confound outcomes of comparisons between SBRT and surgery, as well as a study that evaluated the efficacy of SBRT delivered to patients with larger tumors.

Of the remaining five studies, four were single-institution case series, one of which was prospective and the remaining three were retrospective. One study included data from multiple institutions. The sample sizes for these studies ranged from 59 to 20,111 patients. Each study focused on specific populations of interest, including patients undergoing SBRT in the recurrent setting, patients with larger tumors, and patients who had been diagnosed with intestinal lung disease prior to SBRT and elderly patients. There were no studies found in the update that addressed other subpopulations of patients undergoing SBRT that were highlighted in the ASTRO guideline, including those with centrally located tumors, lack of tissue confirmation of cancer diagnosis, and synchronous or metachronous MPLIC.

No randomized controlled trials met the inclusion criteria for the literature review update. Due to the potential for bias that is associated with nonrandomized study designs, observational studies are usually considered low-quality evidence. These low-quality studies are considered less reliable and have a higher potential for bias. The results of these studies are usually not as strong as those from randomized controlled trials. Therefore, these studies are considered to be of lower quality and are not considered as strong evidence as randomized controlled trials.
OUTCOMES OF INCLUDED STUDIES

Systematic Reviews. Murray et al reported results for 4- to 5-year overall survival and local control with SBRT to be 39.6% (95% CI, 17% to 83%; based on results from eight studies) and 89.6% (95% CI, 83% to 95%, based on results from five studies), respectively. The authors reported that grade 3 and 4 adverse events ranged from 2.7% to 27% across studies. The most common adverse events reported by patients were pneumonitis, dyspnea, chest pain, and pneumonia. Grade 1 and 2 adverse events were common, especially fatigue.

Large administrative database studies (SEER and NCCB). Three retrospective studies from large administrative databases were included.5,10,11 Paul et al3 used the SEER database to explore outcomes for elderly patients (>65 years of age) who underwent SBRT or thoracoscopic resection (sublobar resection in the case of tumors ≤2 cm). The results of their primary analysis comparing patients with tumors ≤5 cm using PMA methods found a significantly improved rate of overall survival with video-assisted thoracoscopic resection versus SBRT (hazard ratio [HR], 1.92; 95% CI, 1.62 to 2.26; P < .001). In a second large database study, Rosen et al5 focused on healthy patients only in their analysis of the NCDB to reduce the potential for bias associated with unhealthy patients being more likely to receive SBRT and also more likely to have worse outcomes. For clinical stage T1 patients, the difference in overall survival was not significant up to 7.5 months after diagnosis; however, after 7.5 months of follow-up, the HR showed a significant difference in favor of patients treated with lobectomy versus SBRT (HR, 0.38; 95% CI, 0.33 to 0.43).12 PMA results demonstrated a median survival of 59% (lobectomy) versus 29% (SBRT; P < .001).13 Another recently published NCDB study included 201 patients who underwent SBRT with tumors ≥5 cm, 15% of whom had also received chemotherapy.14 In this study, the median overall survival was 25.1 months.

Single-institution studies. Patients with larger (≥5 cm) tumors. Tekati et al15 retrospectively explored the use of SBRT in a study of 63 patients who received doses of five fractions delivered in 2 weeks (every other day) or eight fractions delivered in 2.5 weeks at 7.5 Gy per fraction (three or four fractions per week). Patients were followed for a median of 54.7 months, and the local control rate was 95.8% at 2 years, while overall survival was 81% at 2 years and 31.5% at 4 years, and disease-free survival was 82.1% at 2 years. The grade ≥3 toxicity rate was 30%, with radiation pneumonitis the most frequently reported adverse event, affecting 19% of study participants. Fatal toxicity occurred in five of the eight patients (63%) who initially presented with interstitial lung disease (ILD). Patients with pre-existing ILD. Bahig et al16 focused specifically on the subset of patients with preexisting ILD who received SBRT.17 The SBRT doses in this group were according to the STARS (Stereotactic Ablative Radiotherapy in Stage I Non-Small Cell Lung Cancer Patients Who Can Undergo Lobectomy), RTOG 0236, and RTOG 0813 RTCs. The authors found that the ILD-positive patients experienced a significantly greater rate of grade ≥3 radiation pneumonitis compared with the ILD-negative patients (32% vs 4%; P < .001).

SBRT in the recurrent setting. In the only prospective study included in the updated evidence base, Sun et al18 explored the use of SBRT in the recurrent setting, delivered at a dose of 50 Gy in four fractions. After salvage radiation therapy, the rate of local failure calculated using the competing risks method was 3.5% (95% CI, 0.6% to 13.5%) at 1 year and 5.2% (95% CI, 1.7% to 15.7%) at 5 years. The rates of any failure were 15.4% (95% CI, 8.5 to 28.1) at 1 year and 32.8% (95% CI, 22.7 to 47.5) at 5 years. Median overall survival was 63.8 months (95% CI, 46.8 to 80.9 months) from time of salvage radiation therapy. There was an overall rate of grade 2 adverse events of 31%, the most common of which was radiation pneumonitis. Grade 3 adverse events were experienced by three patients (5%), including one instance of dermatitis and two cases of radiation pneumonitis.16

SBRT in an elderly patient population. Another retrospective study19 used propensity matching analysis to compare 35 older (>60 years) matched pairs who underwent either surgery or SBRT. Local recurrence was significantly higher with SBRT compared with surgery (1-, 3-, and 5-year local control rates with surgery: 91.3%, 84.6%, 80.7%, respectively, and 1-, 3-, and 5-year local control rates with SBRT: 78.7%, 71.0%, 53.6%, respectively). Results for overall survival did not differ significantly. This study did not report adverse events.

Multi-institution studies. Patients with larger (≥5 cm) tumors. Verma et al20 analyzed 92 patients from 12 institutions who underwent SBRT for tumors ≥5 cm (median, 5.4 cm; range, 5.0 to 7.5 cm). Median overall survival was 21.4 months, and 2-year survival was 46%. The rate of local control was 95.7% at 1 year and 73.2% at 2 years. The rate of grade ≥3 toxicity was 6.5%. Five grade 3 toxicities were experienced, including one case of dermatitis and four cases of radiation pneumonitis. In addition, one case of grade 5 radiation pneumonitis occurred.

DISCUSSION

ASCO endorses the ASTRO Stereotactic Body Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer Evidence-Based Clinical Practice Guideline with qualifying statements and minor modifications to the ASTRO guideline recommendations. The ASTRO guideline recommendations confirm that surgery remains the standard of care for standard operative risk patients with early-stage NSCLC and provides guidance on the use of SBRT for inoperable patients in more challenging clinical scenarios. The ASCO Expert Panel added minor modifications to several of the recommendations to emphasize the importance of discussing treatment options within the multidisciplinary cancer care team wherever possible. In addition, the Expert Panel emphasized the importance of adequate staging, including PET/CT and invasive staging of mediastinal and hilar nodes with mediastinoscopy or EBUS, in subpopulations with higher rates of nodal metastases, such as patients with tumors ≥5 cm. They also chose to include some qualifying statements and key evidence from the ASTRO guideline narrative to provide context for the recommendations and assist practitioners in implementation of the guideline.

In addition, when reviewing the ASTRO guidelines, the Expert Panel discussed the recommendations for SBRT for tumors abutting or invading the chest wall (Recommendations 3D, 3E). The Panel agreed that while SBRT may be an option for tumors abutting the chest wall, chest wall pain due to rib fracture or irritation of the intercostal nerves due to treatment with SBRT is a common occurrence. The Panel also agreed with the ASTRO guidelines indicating that chest wall pain can be alleviated with conservative management and that prevalence of this toxicity should be discussed with patients with peripheral tumors approximating the chest wall. Few patients with tumors invading the chest wall have been enrolled in prospective trials of SBRT; therefore, the ASCO Expert Panel concluded that a recommendation for or against SBRT could not be endorsed at this time due to the lack of a sufficient body of evidence on outcomes in the population with cT3 tumors <5 cm.4

At this time, there is a lack of strong evidence for use of SBRT in many of the subpopulations addressed in the guideline. As a result, the patient representative on the ASCO Expert Panel highlighted the importance of shared decision making between physicians, patients, and families. She emphasized that benefits and risks can have a different meaning for each patient, and patients and families will vary in their values, goals, and preferences, depending on factors such as overall health, existing comorbidities, and age (J. Feldman, personal communication, April 2017).

The ASCO literature search update resulted in nine new studies added to the evidence base. These additional studies did not present evidence that resulted in any modifications to the ASTRO recommendations. One study demonstrated that patients with preexisting
interstitial lung disease had a significantly higher rate of grade ≥ 3 radiation pneumonitis, and the authors of that study advised that care be taken when weighing the risks and benefits of treatment in that subgroup.

Some patient-matched comparisons of surgery compared with SBRT in our updated literature search, such as an NCDB study of patients without comorbidities, demonstrated significantly better results for patients who underwent surgery. These retrospective, nonrandomized studies have an inherent risk of confounding due their study design; therefore, to improve the evidence base for clinical decision making, adequately powered randomized controlled trials are needed to accurately compared SBRT with surgery. Several prospective studies are currently underway, such as the VALOR (Veterans Affairs Lung cancer surgery Or stereotactic Radiotherapy) study in operable patients (ClinicalTrials.gov identifier: NCT02984761), and the Stablenames trial comparing SBRT to sublobar resection in high-risk patients (ClinicalTrials.gov identifier: NCT02468024). The most relevant comparison may be SBRT versus minimally invasive surgery rather than thoracotomy, which is associated with higher rates of morbidity.

These guidelines, although currently providing the best possible guidance on SBRT in early-stage NSCLC, will be updated as more and better information is published, including new data from ongoing randomized trials.

### ADDITIONAL RESOURCES

More information, including a Data Supplement with the updated search strategy and PRISMA flow diagram, a Methodology Supplement, slide sets, and clinical tools and resources, is available at www.ascos.org/thoracic-cancer-guidelines and www.ascos.org/guidelineswiki. Patient information is available at www.cancer.net. Visit www.ascos.org/guidelineswiki to provide comments on the guideline or to submit new evidence.

### REFERENCES


### Related ASCO Guidelines


### AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at jco.org.

### AUTHOR CONTRIBUTIONS

Administrative support: Erin B. Kennedy
Manuscript writing: All authors
Final approval of manuscript: All authors

718 © 2017 by American Society of Clinical Oncology

JOURNAL OF CLINICAL ONCOLOGY

Downloaded from ascopubs.org by Serena Stockwell on March 5, 2018 from 162.234.150.177. Copyright © 2018 American Society of Clinical Oncology. All rights reserved.

Affiliations
Bryan J. Schneider and Shruti Jolly, University of Michigan, Ann Arbor, MI; Megan E. Daly, University of California, Davis, CA; Erin B. Kennedy, American Society of Clinical Oncology, Alexandria, VA; Mara B. Antonoff, MD Anderson Cancer Center, Houston TX; Stephen Broderick, Johns Hopkins Medicine, Baltimore, MD; Jill Feldman, Lungevity Foundation, Chicago, IL; Bryan Meyers, Washington University, St Louis, MO; Gaetano Rocco, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico, Naples, Italy; Chad Rusthoven, University of Colorado Hospital, Aurora, CO; Ben J. Slotman, Vrije Universiteit Medical Center, Amsterdam, Netherlands; Daniel H. Sterman, New York University Langone Medical Center; and Brendan M. Stiles, Weill Cornell Medical College, New York–Presbyterian Hospital, New York, NY.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Stereotactic Body Radiotherapy for Early-Stage Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Bryan J. Schneider
Consulting or Advisory Role: Clovis Oncology, Genentech
Research Funding: MedImmune (Inst), Genentech (Inst), OncoMed Pharmaceuticals (Inst), Bristol-Myers Squibb (Inst), MacroGenics (Inst)

Megan E. Daly
Employment: University of California, Davis
Research Funding: EMD Serono

Erin B. Kennedy
No relationship to disclose

Mara B. Antonoff
No relationship to disclose

Stephen Broderick
Consulting or Advisory Role: Bristol-Myers Squibb (Inst)

Jill Feldman
No relationship to disclose

Shruti Jolly
Honoraria: Varian Medical Systems

Bryan Meyers
Honoraria: Intuitive Surgical, Ethicon
Research Funding: Ethicon, Varian Medical Systems (Inst)

Gaetano Rocco
Honoraria: Medtronic, Baxter, Ethicon, Scanlan
Consulting or Advisory Role: Medtronic, Baxter (Inst), Ethicon
Speakers’ Bureau: Scanlan, Medtronic, Ethicon, Baxter
Research Funding: Baxter (Inst)
Patents, Royalties, Other Intellectual Property: I designed a new surgical instrument for Scanlan
Travel, Accommodations, Expenses: Baxter, Medtronic, Ethicon, Scanlan

Chad Rusthoven
Honoraria: ARIAD Pharmaceuticals

Ben J. Slotman
Honoraria: Varian Medical Systems, ViewRay
Consulting or Advisory Role: Varian Medical Systems (Inst), ViewRay (Inst)
Research Funding: Varian Medical Systems (Inst), ViewRay (Inst)

Daniel H. Sterman
Consulting or Advisory Role: Olympus Medical Systems, Ethicon, CSA Medical

Brendon M. Stiles
Employment: Pfizer (I)
Leadership: Pfizer (I)
Stock or Other Ownership: Pfizer (I)
Consulting or Advisory Role: Merck
Travel, Accommodations, Expenses: Merck
## Acknowledgment

The Expert Panel thanks Natasha B. Leighl, MD, and the Clinical Practice Guidelines Committee for their thoughtful reviews and insightful comments on this guideline endorsement.

## Appendix

| Table A1. Original ASTRO and ASCO Endorsed Research Questions, Recommendations, and Qualifying Statements |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| **ASTRO Recommendation** | **ASCO Endorsed Recommendation** | **ASTRO Evidence Rating and Strength of Recommendations** |
| **Key Question 1: When is SBRT appropriate for patients with T1-2, N0 NSCLC who are medically operable?** | **Recommendation 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon, preferably within a multidisciplinary cancer care team, to determine operability. The decision to undergo an operation should be made by the surgeon and patient, in collaboration with family members. Some criteria that have been used to define operative risk are listed in the qualifying statements under Recommendation 1C.** | **Strength of recommendation: strong; Quality of evidence: moderate** |
| **Recommendation 1A:** Any patient with operable stage I NSCLC being considered for SBRT should be evaluated by a thoracic surgeon, preferably within a multidisciplinary setting, to reduce specialty bias. | **Recommendation 1B: For patients with standard operative risk (i.e., with anticipated operative mortality of < 1.5%) and stage I NSCLC, SBRT is not recommended as an alternative to surgery outside of a clinical trial. Discussions about SBRT are appropriate, with the disclosure that long-term outcomes with SBRT > 3 years are not well-established. For this population, lobectomy with systematic mediastinal/hilar lymph node evaluation remains the recommended treatment, though a sublobar resection may be considered in select clinical scenarios.** | **Strength of recommendation: strong; Quality of evidence: high** |
| **Recommendation 1C:** For patients with high operative risk (i.e., those who cannot tolerate lobectomy, but are candidates for sublobar resection) stage I NSCLC, discussions about SBRT as a potential alternative to surgery are encouraged. Patients should be informed that while SBRT may have decreased risks from treatment in the short term, the longer-term outcomes > 3 years are not well-established. | **Recommendation 1C: For patients with high operative risk stage I NSCLC, discussions about SBRT as a potential alternative to surgery are encouraged within the multidisciplinary cancer care team. In cases where SBRT is offered, patients should be informed that while SBRT may have decreased risks from treatment in the short term, the longer-term outcomes > 3 years are not well-established.** | **Strength of recommendation: conditional; Quality of evidence: moderate** |
| **ASTRO qualifying statement:** Where multidisciplinary consultation and patient preference result in a decision to perform resection in high operative risk patients, limited resection (segmentectomy or wedge resection), rather than lobectomy, is more commonly selected. At this time, there have been no prospective randomized trials completed that directly compare limited resection with SBRT or lobectomy. **ASTRO qualifying statement:** While there is no universally accepted definition, high operative risk has been defined by various studies as “FEV1 < 50% predicted, DCO < 50% predicted, or a combination of advanced age, impaired pulmonary function, pulmonary hypertension, and poor left ventricular function. Operative risk should be assessed by a thoracic surgeon who specializes in lung resections.” | **ASTRO qualifying statement:** Longer-term data from the RTOG 0236 phase II trial of inoperable T1-T2N0M0 tumors ≤ 5 cm showed that rates of 5-year primary tumor, in- lobe, and locoregional failure were 7%, 20%, and 38%, respectively. Overall survival at 5 years was 40%. Treatment-related grade 3, grade 4, and grade 5 adverse events were reported in 27%, 4%, and 0% of patients, respectively. | |
| **Key Question 2 (part 1): When is SBRT appropriate for medically inoperable patients with T1-2, N0 NSCLC?** | **Recommendation 2A: SBRT directed toward centrally located lung tumors carries unique and significant risks when compared with treatment directed at peripherally located tumors. The use of 3 fraction regimens should be avoided in this setting.** | **Strength of recommendation: strong; Quality of evidence: high** |
| **Recommendation 2A:** SBRT directed toward centrally located lung tumors carries unique and significant risks when compared with treatment directed at peripherally located tumors. The use of 3 fraction regimens is not recommended in this setting. **ASCO qualifying statement:** There is a significant rate of nodal disease in this population; therefore, pretreatment staging with PET/CT and invasive mediastinal/hilar staging with EBUS/mediastinoscopy is recommended. | | |
| **Recommendation 2B:** SBRT directed toward centrally located lung tumors carries unique and significant risks when compared with treatment directed at peripherally located tumors. The use of 3 fraction regimens is not recommended in this setting. **ASCO qualifying statement:** There is a significant rate of nodal disease in this population; therefore, pretreatment staging with PET/CT and invasive mediastinal/hilar staging with EBUS/mediastinoscopy is recommended. | | |
| **Recommendation 2C:** SBRT directed toward centrally located lung tumors carries unique and significant risks when compared with treatment directed at peripherally located tumors. The use of 3 fraction regimens is not recommended in this setting. **ASCO qualifying statement:** There is a significant rate of nodal disease in this population; therefore, pretreatment staging with PET/CT and invasive mediastinal/hilar staging with EBUS/mediastinoscopy is recommended. | | |

Downloaded from ascopubs.org by Serena Stockwell on March 5, 2018 from 162.234.150.177
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
Table A1. Original ASTRO and ASCO Endorsed Research Questions, Recommendations, and Qualifying Statements (continued)

<table>
<thead>
<tr>
<th>ASTRO Recommendation</th>
<th>ASCO Endorsed Recommendation</th>
<th>ASTRO Evidence Rating and Strength of Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommendation 2B: SBRT directed at central lung tumors should be delivered in 4 or 5 fractions. Adherence to volumetric and maximum dose constraints may optimize the safety profile of this treatment. For central tumors for which SBRT is deemed too high-risk, hypofractionated radiotherapy utilizing 6-15 fractions can be considered.</td>
<td>Recommendation 2B: Providers should use caution when considering SBRT for central tumors. Delivery of SBRT in more than 3 (ie, 4 or 5) fractions may reduce the risk of severe toxicity. Adherence to volumetric and maximum dose constraints may optimize the safety profile of this treatment. For central tumors for which SBRT is deemed too high-risk (eg, tumors directly abutting or invading the esophagus or proximal bronchial tree), hypofractionated radiotherapy utilizing 6-15 fractions or conventionally fractionated radiotherapy may be considered. ASTRO qualifying statement: Caution is recommended due to the potential for serious toxicity to normal centrally located tissues. “In this setting, adequate informed consent to patients—including a discussion of patient risk tolerance and goals of care—is a necessary part of communication between radiation oncologists and patients”1-3</td>
<td>Strength of recommendation: conditional; Quality of evidence: moderate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ASCO qualifying statement: The RTOG 0813 phase I/II study aimed to evaluate escalating radiation doses ranging from 50 to 60 Gy in five fractions delivered every other day to central tumors ≤ 5 cm (including tumors within 2 cm of the tracheobronchial tree, and abutting the pericardium, mediastinum, or spine). Four patients, including one treated to 10.5 Gy × 5, two treated to 11.5 Gy × 5, and one treated to 12 Gy × 5, experienced grade 5 or fatal adverse events, while those treated at the lowest dose level did not experience any grade ≥ 3 events. We are currently awaiting mature, long-term efficacy results presented in full manuscript form from this trial. These results will be used to determine whether there is a dose that results in an acceptable balance of tumor control and toxicity.</td>
</tr>
<tr>
<td>Key Question 2 (part 2): When is SBRT appropriate for medically inoperable patients with T1-2, NO NSCLC: for patients with tumors &gt; 5 cm in diameter.</td>
<td>Key Question 2 (part 2): When is SBRT appropriate for medically inoperable patients with T1-2, NO NSCLC: for patients with tumors &gt; 5 cm in diameter.</td>
<td></td>
</tr>
<tr>
<td>Recommendation 2C: SBRT may be an appropriate option for select tumors &gt; 5 cm in diameter with an acceptable therapeutic ratio. Adherence to volumetric and maximum dose constraints may optimize the safety profile of this treatment.</td>
<td>Recommendation 2C: SBRT may be an appropriate option for select tumors &gt; 5 cm in diameter with an acceptable therapeutic ratio. Adherence to volumetric and maximum dose constraints may optimize the safety profile of this treatment.</td>
<td>Strength of recommendation: low; Quality of evidence: low</td>
</tr>
<tr>
<td>Definition: Therapeutic ratio refers to a treatment schedule that balances maximizing tumor cell kill while minimizing radiation-induced acute and late morbidity to surrounding critical structures.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASCO qualifying statement: There is a significant rate of nodal disease (locate reference) in this population; therefore, accurate pretreatment invasive mediastinal/hilar staging with EBUS/mediastinoscopy is recommended.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASCO qualifying statement: Chemotherapy is currently recommended as the standard treatment of tumors &gt; 4 cm after surgical resection. Adjuvant therapy may also be considered after SBRT; however, limited data are available to support its use.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key Question 2 (part 3): When is SBRT appropriate for medically inoperable patients with T1-2, NO NSCLC: for patients lacking tissue confirmation (diagnosis):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recommendation 2D: Whenever possible, obtain a biopsy prior to treatment with SBRT to confirm a histologic diagnosis of a malignant lung nodule.</td>
<td>Recommendation 2D: Whenever possible, obtain a biopsy prior to treatment with SBRT to confirm a histologic diagnosis of a malignant lung nodule.</td>
<td>Strength of recommendation: high; Quality of evidence: high</td>
</tr>
<tr>
<td>Recommendation 2E: SBRT can be delivered in patients who refuse a biopsy, have undergone nondiagnostic biopsy, or who are thought to be at prohibitive risks of biopsy. Prior to SBRT in patients lacking tissue confirmation of malignancy, patients are recommended to be discussed in a multidisciplinary manner with a consensus that the lesion is radiographically and clinically consistent with a malignant lung lesion based on tumor, patient, and environmental factors.</td>
<td>Recommendation 2E: SBRT may be delivered in patients who refuse a biopsy, have undergone nondiagnostic biopsy, or who are thought to be at prohibitive risks of biopsy. Prior to SBRT in patients lacking tissue confirmation of malignancy, treatment options should be discussed within a multidisciplinary cancer care team with a consensus that the lesion is radiographically and clinically consistent with a malignant lung lesion based on tumor, patient, and environmental factors. ASTRO Qualifying statement: Tumor-specific factors to consider include lesion size, growth over time, presence of spiculations or lack of benign-appearing calcifications, PET avidity, and lesion location. Other patient-specific factors, such as smoking history or history of prior lung cancers, should also be considered. Regional environmental factors, such as the incidence of histoplasmosis, may affect the probability that a lesion is a malignant and should also be considered in the calculation of obtaining histologic confirmation. ASCO qualifying statement: Patients should be staged with PET/CT and mediastinal/hilar nodal sampling when feasible. ASCO qualifying statement: For patients deemed to be at prohibitive risk of biopsy, a multidisciplinary discussion should occur to ensure that safe means of obtaining tissue are not feasible (eg, transbronchial biopsy, etc). In addition, consideration should also be given as to whether treatment would pose prohibitive risks. The goals, expectations, and potential increased risks of SBRT should be carefully weighed and discussed with the patient and family in the context of shared decision making.</td>
<td>Strength of recommendation: moderate; Quality of evidence: moderate</td>
</tr>
<tr>
<td>(continued on following page)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table A1. Original ASTRO and ASCO Endorsed Research Questions, Recommendations, and Qualifying Statements (continued)

| Key Question 2 (part 4): When is SBRT appropriate for medically inoperable patients with T1-2, N0 NSCLC: for patients with synchronous or multifocal tumors: |
| Recommendation 2F: Multiple primary lung cancers (MPLC) can be difficult to differentiate from intrathoracic metastatic lung cancer and pose unique issues for parenchymal preservation; therefore, it is recommended that they are evaluated by a multidisciplinary cancer care team. | Recommendation 2F: Multiple primary lung cancers (MPLC) can be difficult to differentiate from intrathoracic metastatic lung cancer and pose unique issues for parenchymal preservation; therefore, it is recommended that they are evaluated by a multidisciplinary cancer care team. | Strength of recommendation: moderate; Quality of evidence: moderate |
| Recommendation 2G: PET/CT and brain MRI are recommended in patients suspected of having MPLC to help differentiate from intrathoracic metastatic lung cancer. Invasive mediastinal/hilar staging with EBUS/mediastinoscopy should be strongly considered. | Recommendation 2G: PET/CT and brain MRI are recommended in patients suspected of having MPLC to help differentiate from intrathoracic metastatic lung cancer. Invasive mediastinal/hilar staging with EBUS/mediastinoscopy should be strongly considered. | Strength of recommendation: strong; Quality of evidence: moderate |
| Recommendation 2H: SBRT may be considered as a curative treatment option for patients with synchronous MPLC. SBRT for synchronous MPLC has equivalent rates of local control and toxicity but decreased rates of overall survival compared with those with single tumors. | Recommendation 2H: SBRT may be considered by the multidisciplinary cancer care team as a potentially curative treatment option for patients with synchronous MPLC. ASTRO qualifying statement: SBRT for synchronous MPLC has equivalent rates of local control and toxicity but decreased rates of overall survival compared with SBRT for single tumors. The decision to treat multiple lesions with SBRT is an individualized process that should be discussed by a multidisciplinary cancer care team, as this approach may increase radiation doses to normal tissues and increase the risk of toxicity in some cases. | Strength of recommendation: conditional; Quality of evidence: low |
| Recommendation 2I: SBRT is recommended as a curative treatment option for patients with metachronous MPLC. SBRT for metachronous MPLC has equivalent rates of local control and toxicity and overall survival compared with those with single tumors. | Recommendation 2I: SBRT may be considered by the multidisciplinary cancer care team as a potentially curative treatment option for patients with metachronous MPLC. ASTRO qualifying statement: SBRT for metachronous MPLC has comparable rates of local control and toxicity and overall survival compared with single tumors. | Strength of recommendation: strong; Quality of evidence: moderate |

Key Question 2 (part 5): When is SBRT appropriate for medically inoperable patients with T1-2, N0 NSCLC: for patients who underwent pneumonectomy and now have a new primary tumor in their remaining lung: |

| Recommendation 2J: SBRT may be considered a curative treatment option for patients with metachronous MPLC in a post-pneumonectomy setting. While SBRT for metachronous MPLC appears to have equivalent rates of local control and acceptable toxicity compared with single tumors, SBRT in the post-pneumonectomy setting might have a higher rate of toxicity than in patients with higher baseline lung capacity. | Recommendation 2J: SBRT may be considered by the multidisciplinary cancer care team as a potentially curative treatment option for patients with metachronous MPLC in a post-pneumonectomy setting. ASTRO qualifying statement: “While SBRT for metachronous MPLC appears to have equivalent rates of local control and acceptable toxicity compared with single tumors, SBRT in the post-pneumonectomy setting might have a higher rate of toxicity than in patients with higher baseline lung capacity.” Delivery of SBRT would depend on tumor location, size, and patient comorbidities and patients should be thoroughly evaluated by a multidisciplinary cancer care team. ASTRO qualifying statement: “Generally, great caution should be taken to minimize the dose to the single lung, as high grade radiation pneumonitis in a single lung may be a serious and potentially life-threatening toxicity.” The potential for radiation pneumonitis should be discussed with patients, and a pulmonary evaluation should be obtained, including pulmonary function tests and consideration of a pulmonary evaluation by a dedicated pulmonologist. | Strength of recommendation: conditional; Quality of evidence: low |

Key Question 3 (part 1): For patients with medically inoperable early-stage lung cancer, how can SBRT techniques be individually tailored to provide an adequate dose for tumor eradication with minimal risk to normal structures in high-risk clinical scenarios, including: for tumors with intimal proximity/involvement of mediastinal structures (bronchial tree, esophagus, heart, etc): |

| Recommendation 3A: For tumors in close proximity to the proximal bronchial tree, SBRT should be delivered in 4-5 fractions. Physicians should endeavor to meet the constraints that have been used in prospective studies given the severe toxicities that have been reported. | Recommendation 3A: Providers should use caution when considering SBRT for tumors in close proximity to the proximal bronchial tree. Delivery of SBRT in 4-5 fractions may reduce the risks of severe toxicity. Physicians should endeavor to meet the constraints that have been used in prospective studies given the severe toxicities that have been reported. ASTRO qualifying statement: There are a limited number of retrospective studies that report the use of SBRT in patients with tumors abutting the proximal bronchial tree. Patients with tumors abutting the proximal airways should be counseled about the potential for fatal treatment complications, even when dose constraints and highly conformal SBRT techniques are used. ASCO qualifying statement: Appropriate staging, including PET/CT and invasive mediastinal/hilar staging with EBUS/mediastinoscopy, are recommended due to the high risk of nodal disease in this patient population. | Strength of recommendation: strong; Quality of evidence: low |

(continued on following page)
<table>
<thead>
<tr>
<th>ASTRO Recommendation</th>
<th>ASCO Endorsed Recommendation</th>
<th>ASTRO Evidence Rating and Strength of Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendation 3B:</strong> For tumors in close proximity to the esophagus, physicians should endeavor to meet the constraints that have been used in prospective studies or otherwise reported in the literature given the severe esophageal toxicities that have been reported.</td>
<td><strong>Recommendation 3B:</strong> Where a discussion within the multidisciplinary cancer care team results in a recommendation for SBRT for tumors in close proximity to the esophagus, physicians should endeavor to meet the constraints that have been used in prospective studies or otherwise reported in the literature given the severe esophageal toxicities that have been reported.</td>
<td>Strength of recommendation: low; Quality of evidence: low</td>
</tr>
<tr>
<td><strong>Recommendation 3C:</strong> For tumors in close proximity to the heart and pericardium, SBRT should be delivered in 4-5 fractions with low incidence of serious toxicities to the heart, pericardium, and large vessels observed. Adherence to volumetric and maximum dose constraints used in prospective trials or reported in the literature may optimize the safety profile of this treatment.</td>
<td><strong>Recommendation 3C:</strong> For tumors in close proximity to the heart and pericardium, SBRT should be delivered in 4-5 fractions with low incidence of serious toxicities to the heart, pericardium and large vessels observed. Adherence to volumetric and maximum dose constraints used in prospective trials or reported in the literature may optimize the safety profile of this treatment.</td>
<td>Strength of recommendation: strong; Quality of evidence: low</td>
</tr>
<tr>
<td><strong>Key Question 4 (part 1):</strong> In medically inoperable patients, what is the role of SBRT as salvage therapy for early-stage lung cancer that recurs? After conventionally fractionated radiation.3</td>
<td><strong>Key Question 4 (part 2):</strong> For patients with medically inoperable early-stage lung cancer, how can SBRT techniques be individually tailored to provide an adequate dose for tumor eradication with minimal risk to normal structures in high-risk clinical scenarios, including: for tumors abutting or invading the chest wall:</td>
<td></td>
</tr>
<tr>
<td><strong>Recommendation 3D:</strong> SBRT is an appropriate option for treatment and should be offered for T1-2 that abut the chest wall. Grade 1 and 2 chest wall toxicity is a common occurrence post SBRT that usually resolves with conservative management. Patients with peripheral tumors approximating the chest wall should be counseled on the possibility of this common toxicity.</td>
<td><strong>Recommendation 3D:</strong> SBRT is an appropriate option for treatment and may be offered for T1-2 tumors that abut the chest wall. Grade 1 and 2 chest wall toxicity, presenting most commonly as pain due to rib fracture or irritation of the intercostal nerves, is a common occurrence post SBRT that usually resolves with conservative management. Patients with peripheral tumors approximating the chest wall should be counseled on the possibility of this common toxicity.</td>
<td>Strength of recommendation: strong; Quality of evidence: high</td>
</tr>
<tr>
<td><strong>Recommendation 3E:</strong> SBRT may be used in patients with cT3 disease due to chest wall invasion without clear evidence of reduced efficacy or increased toxicity compared with tumors abutting the chest wall.</td>
<td><strong>Recommendation 3E:</strong> Until further evidence becomes available to inform the topic, the ASCO Expert Panel defers a decision for or against endorsement of the use of SBRT in patients with cT3 disease due to chest wall invasion.</td>
<td></td>
</tr>
<tr>
<td><strong>Key Question 5 (part 1):</strong> In medically inoperable patients, what is the role of SBRT as salvage therapy for early-stage lung cancer that recurs? After conventionally fractionated radiotherapy:</td>
<td><strong>Recommendation 4A:</strong> The use of salvage SBRT after primary conventionally fractionated radiation may be offered to selected patients due to reported favorable local control and survival.</td>
<td>Strength of recommendation: conditional; Quality of evidence: low</td>
</tr>
<tr>
<td><strong>Recommendation 4B:</strong> Patients treated with salvage SBRT after primary conventionally fractionated radiation should be informed of significant (including fatal) toxicities.</td>
<td><strong>Recommendation 4B:</strong> See qualifying statements for recommendation 4A.</td>
<td>Strength of recommendation: strong; Quality of evidence: low</td>
</tr>
</tbody>
</table>

(continued on following page)
Table A1. Original ASTRO and ASCO Endorsed Research Questions, Recommendations, and Qualifying Statements (continued)

<table>
<thead>
<tr>
<th>ASTRO Recommendation</th>
<th>ASCO Endorsed Recommendation</th>
<th>ASTRO Evidence Rating and Strength of Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommendation 4C: Patient selection for salvage SBRT after primary conventionally fractionated radiation is a highly individualized process. Radiation oncologists should assess evidence-based patient, tumor, and treatment factors prior to treatment initiation.</td>
<td>Recommendation 4C: Patient selection for salvage SBRT after primary conventionally fractionated radiation, SBRT, or sublobar resection is a highly individualized process. Radiation oncologists should assess evidence-based patient, tumor, and treatment factors prior to treatment initiation. ASTRO qualifying statement: “Salvage SBRT treatment plans should ideally be reviewed with medical physics and other radiation oncologists (in a peer review quality assurance setting) to ensure high-quality results to optimize patient selection, maximize local control and survival, and minimize treatment toxicities.”3 ASTRO qualifying statement: Toxicities vary on an individual basis depending on patient’s health, prior treatment, comorbidities, etc. and should be discussed within the multidisciplinary cancer care team. “Predictors of toxicity for SBRT salvage include central tumor location, in-field recurrence, larger treatment volumes, bilateral mediastinal primary PTV targets, composite lung V20 ≥ 30%, 6 FEV1 ≤ 65%, 7 and poor baseline performance status.”3</td>
<td>Strength of recommendation: strong; Quality of evidence: low</td>
</tr>
<tr>
<td>Key Question 4 (part 2): In medically inoperable patients, what is the role of SBRT as salvage therapy for early-stage lung cancer that recurs? After SBRT:</td>
<td>Key Question 4 (part 3): In medically inoperable patients, what is the role of SBRT as salvage therapy for early-stage lung cancer that recurs? After sublobar resection:</td>
<td>Key Question 4 (part 4): In medically inoperable patients, what is the role of SBRT as salvage therapy for early-stage lung cancer that recurs? After concurrent chemoradiotherapy:</td>
</tr>
<tr>
<td>Patients’ values, goals and preferences:</td>
<td>ASCO qualifying statement: In written comments, the ASCO Expert Panel Patient Representative noted that there is a lack of strong evidence for many of the guideline recommendations. Thus, the Representative emphasized the importance of shared decision-making between physicians, patients and families in this context, because benefits and risks can have a different meaning for each patient, and patients and families will vary in their values, goals and preferences, depending on factors such as overall health, comorbidities and age (J. Feldman, personal communication, April 2017).</td>
<td></td>
</tr>
</tbody>
</table>

NOTE. The ASCO Expert Panel’s modifications and qualifying statements to ASTRO’s recommendations appear in bold.

Abbreviations: ASTRO, American Society for Radiation Oncology; CT, computed tomography; DLCO, diffusing capacity of the lungs for carbon monoxide; EBUS, endobronchial ultrasound; MPLC, multiple primary lung cancers; MRI, magnetic resonance imaging; NSCLC, non–small-cell lung cancer; PTV, planning target volume; RTOG, Radiation Therapy Oncology Group; SBRT, stereotactic body radiotherapy; V20, percentage of lung volume (with subtraction of the volume involved by lung cancer) that receives radiation doses of 20 Gy or more.

Table A2. ASCO Endorsement of the American Society for Radiation Oncology Guideline for Stereotactic Body Radiotherapy in Early-Stage Non–Small-Cell Lung Cancer Expert Panel Membership

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bryan J. Schneider, MD, Co-Chair</td>
<td>University of Michigan, Ann Arbor, MI</td>
</tr>
<tr>
<td>Megan E. Daly, MD</td>
<td>University of California, Davis, CA</td>
</tr>
<tr>
<td>Mara B. Antonoff, MD</td>
<td>MD Anderson Cancer Center, Houston TX</td>
</tr>
<tr>
<td>Stephen Broderick, MD</td>
<td>Johns Hopkins Medicine, Baltimore, MD</td>
</tr>
<tr>
<td>Shruti Jolly, MD</td>
<td>University of Michigan, Ann Arbor, MI</td>
</tr>
<tr>
<td>Jill Feldman, Patient Representative</td>
<td>Lungevity Foundation, Chicago, IL</td>
</tr>
<tr>
<td>Bryan Meyers, MD</td>
<td>Washington University, St Louis, MO</td>
</tr>
<tr>
<td>Gaetano Rocco, MD</td>
<td>Istituto Nazionale Tumori, IRCCS, Naples, Italy</td>
</tr>
<tr>
<td>Chad Rusthoven, MD, Practice Guidelines Implementation Representative</td>
<td>University of Colorado Hospital, Aurora, CO</td>
</tr>
<tr>
<td>Ben J. Slotman, MD, PhD</td>
<td>Vrije Universiteit Medical Center, Amsterdam, Netherlands</td>
</tr>
<tr>
<td>Daniel H. Sterman, MD</td>
<td>NYU Langone Medical Center, New York, NY</td>
</tr>
<tr>
<td>Brendon Stiles, MD, Co-Chair</td>
<td>Weil Cornell Medical College, New-York Presbyterian Hospital, New York, NY</td>
</tr>
</tbody>
</table>

NOTE. ASCO Staff: Erin B. Kennedy, MHSc.
Stereotactic body radiotherapy (SBRT) is a definitive local treatment option for patients with stage I non-small cell lung cancer (NSCLC) who are not surgical candidates and patients who refuse surgery. The purpose of this study was to assess the impact of SBRT on T1â€“T2 NSCLC from a national registry, reflecting practices and outcomes in a real-world setting.